Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Industry: Medical Devices (Interventional Cardiology, Peripheral Interventions, Neurovascular, Electrophysiology, Endosurgery, Oncology, Urology, Gynecology)
Boston Scientific is a global developer and manufacturer of medical devices focused on less-invasive medicine. The company operates through two primary business groups: Cardiovascular (72% of 2003 net sales) and Endosurgery (28% of 2003 net sales). International sales accounted for approximately 45% of total net sales. The company employs approximately 15,000 people worldwide.
Key Financial Metrics
Revenue: Approximately $3.5 billion in net sales for 2003 (up from $1.8 million in 1979).
Research & Development: Approximately $450 million (13% of net sales).
Strategic Investments: More than $350 million invested in approximately 25 strategic initiatives (acquisitions and alliances) in 2003.
Market Capitalization: Approximately $19.7 billion (based on non-affiliate holdings as of June 30, 2003).
Stock Price: $40.85 (closing price as of February 27, 2004).
Shares Outstanding: 833,117,550 (as of February 27, 2004).
Note: Specific figures for net income, operating profit, cash flow, debt, and liquidity are incorporated by reference to the Consolidated Financial Statements (Exhibit 13.1) and are not explicitly detailed in the provided text.
Material Changes and Strategic Developments
- Drug-Eluting Stent Launch: Successfully launched the TAXUS paclitaxel-eluting coronary stent system in Europe and certain international markets during 2003, achieving market leadership in those regions. U.S. launch occurred in Q1 2004.
- Product Portfolio Expansion: Launched the Liberte coronary stent in Europe (Jan 2004) and the Cutting Balloon Ultra microsurgical dilatation device in U.S. and European markets.
- Operational Consolidation: Completed a global operations plan consolidating manufacturing along product lines, shifting production to Miami and Ireland, and discontinuing operations at three U.S. facilities to improve efficiency.
- Branding: Implemented a master branding initiative to unify the company's identity under the "Boston Scientific" name.
Outlook, Risks, and Contingencies
Outlook: Management expects significant revenue growth driven by the U.S. adoption of the TAXUS drug-eluting stent and the launch of the Liberte stent. The company anticipates the worldwide coronary stent market could grow to over $5 billion annually.
Key Risks:
- Patent Litigation: Significant ongoing litigation with Johnson & Johnson (Cordis) regarding stent patents. A jury previously awarded Cordis $324 million, though the award was set aside and a new trial was ordered. The company also settled all outstanding litigation with Guidant Corporation in February 2004.
- Regulatory and Reimbursement: Risks associated with delayed regulatory approvals (FDA, CE Mark) and potential changes in third-party reimbursement policies, particularly in Japan and Europe.
- Market Competition: High competition in the coronary stent market, including the alliance between Cordis and Guidant to co-promote drug-eluting stents.
- Self-Insurance: The company is substantially self-insured for general and product liability claims due to the unavailability of affordable third-party coverage, increasing exposure to catastrophic losses.
Investor Verification Checklist
- Verify the final outcome and financial impact of the patent litigation with Johnson & Johnson (Cordis), specifically regarding the $324 million damage award history and the status of the new trial.
- Review the Consolidated Financial Statements (Exhibit 13.1) for specific net income, operating margin, and cash flow figures not detailed in the text summary.
- Monitor the adoption rate and reimbursement status of the TAXUS drug-eluting stent in the U.S. market following its Q1 2004 launch.
- Assess the impact of the self-insurance strategy on future earnings volatility regarding product liability claims.
- Confirm the regulatory approval timeline for the Liberte coronary stent in the U.S. (expected H2 2004).